Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Scott Eliasof, Ph.D VP of Research at Cerulean presents at Molecular Targets press briefingBoston – at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference today we heard about CRLX101 (Cerulean Pharmaceuticals), a nanopharmaceutical in phase 2 development. The presentation highlighted the challenges and opportunities in cancer drug development.

This post is not intended to be a detailed review of the preclinical data presented, but offers a summary of the value proposition, the intended target and the insights we took away from a press briefing at the conference.

Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content. 

This content is restricted to subscribers

Posted by 

2 Responses to “Cerulean CRLX101 Challenges and Opportunities”

  1. AmandaT

    Couldn’t agree more… HIF is not a proven target and thus far nothing targeting HIF has made it beyond very early clinical. Yes, there is a rationale in RCC but no, there is no clinical evidence. Further to muddy the waters this apparently is also a camptothecin topo-I inhibitor so even a successful result wouldn’t be PoC for HIF. I would love to be proved wrong but I wish VC analysts would make better choices both for their company’s sake and for the sake of the patients who take part in trials.

    • maverickny

      I couldn’t agree more with your well argued sentiments, Amanda. This one seemed a bit of a wild shot, frankly.

Comments are closed.

Sign Up for New Post Alerts
error: Content is protected !!